(Q33383894)

26 July 2017

1 reference

title

New-generation drugs that stimulate platelet production in chronic immune thrombocytopenic purpura (English)

1 reference

Immune thrombocytopenic purpura

26 July 2017

1 reference

1 reference

Alan T Nurden

1

1 reference

26 July 2017

Jean-François Viallard

series ordinal

2

1 reference

26 July 2017

Paquita Nurden

series ordinal

3

1 reference

26 July 2017

language of work or name

English

0 references

publication date

25 March 2009

1 reference

26 July 2017

1 reference

26 July 2017

373

1 reference

26 July 2017

9674

1 reference

26 July 2017

1562-1569

1 reference

Guidelines for the investigation and management of idiopathic thrombocytopenic purpura in adults, children and in pregnancy

26 July 2017

1 reference

https://api.crossref.org/works/10.1016%2FS0140-6736%2809%2960255-5

7 January 2021

Update on the management of immune thrombocytopenic purpura in children

1 reference

https://api.crossref.org/works/10.1016%2FS0140-6736%2809%2960255-5

7 January 2021

Pathogenesis of chronic immune thrombocytopenic purpura

1 reference

https://api.crossref.org/works/10.1016%2FS0140-6736%2809%2960255-5

7 January 2021

Immune thrombocytopenic purpura in adults

1 reference

https://api.crossref.org/works/10.1016%2FS0140-6736%2809%2960255-5

7 January 2021

Megakaryocyte development and platelet production.

1 reference

https://api.crossref.org/works/10.1016%2FS0140-6736%2809%2960255-5

7 January 2021

Dynamic Visualization of Thrombopoiesis Within Bone Marrow

1 reference

https://api.crossref.org/works/10.1016%2FS0140-6736%2809%2960255-5

7 January 2021

The molecular and cellular biology of thrombopoietin: the primary regulator of platelet production

1 reference

https://api.crossref.org/works/10.1016%2FS0140-6736%2809%2960255-5

7 January 2021

Programmed anuclear cell death delimits platelet life span.

1 reference

https://api.crossref.org/works/10.1016%2FS0140-6736%2809%2960255-5

7 January 2021

Mechanisms of thrombocytopenia in chronic autoimmune thrombocytopenic purpura. Evidence of both impaired platelet production and increased platelet clearance

1 reference

https://api.crossref.org/works/10.1016%2FS0140-6736%2809%2960255-5

7 January 2021

Defective circulating CD25 regulatory T cells in patients with chronic immune thrombocytopenic purpura

1 reference

https://api.crossref.org/works/10.1016%2FS0140-6736%2809%2960255-5

7 January 2021

T-cell-mediated cytotoxicity toward platelets in chronic idiopathic thrombocytopenic purpura

1 reference

https://api.crossref.org/works/10.1016%2FS0140-6736%2809%2960255-5

7 January 2021

Immune thrombocytopenic purpura (ITP) plasma and purified ITP monoclonal autoantibodies inhibit megakaryocytopoiesis in vitro

1 reference

https://api.crossref.org/works/10.1016%2FS0140-6736%2809%2960255-5

7 January 2021

Ultrastructural study shows morphologic features of apoptosis and para-apoptosis in megakaryocytes from patients with idiopathic thrombocytopenic purpura

1 reference

https://api.crossref.org/works/10.1016%2FS0140-6736%2809%2960255-5

7 January 2021

Recruitment of T cells into bone marrow of ITP patients possibly due to elevated expression of VLA-4 and CX3CR1.

1 reference

https://api.crossref.org/works/10.1016%2FS0140-6736%2809%2960255-5

7 January 2021

Congenital disorders associated with platelet dysfunctions

1 reference

https://api.crossref.org/works/10.1016%2FS0140-6736%2809%2960255-5

7 January 2021

The epidemiology of immune thrombocytopenic purpura

1 reference

https://api.crossref.org/works/10.1016%2FS0140-6736%2809%2960255-5

7 January 2021

Novel approaches to refractory immune thrombocytopenic purpura

1 reference

https://api.crossref.org/works/10.1016%2FS0140-6736%2809%2960255-5

7 January 2021

Intravenous (IV) anti-D and IV immunoglobulin achieve acute platelet increases by different mechanisms: modulation of cytokine and platelet responses to IV anti-D by FcgammaRIIa and FcgammaRIIIa polymorphisms

1 reference

https://api.crossref.org/works/10.1016%2FS0140-6736%2809%2960255-5

7 January 2021

Intravenous immunoglobulin ameliorates ITP via activating Fc gamma receptors on dendritic cells

1 reference

https://api.crossref.org/works/10.1016%2FS0140-6736%2809%2960255-5

7 January 2021

Recapitulation of IVIG anti-inflammatory activity with a recombinant IgG Fc.

1 reference

https://api.crossref.org/works/10.1016%2FS0140-6736%2809%2960255-5

7 January 2021

Splenectomy for adult patients with idiopathic thrombocytopenic purpura: a systematic review to assess long-term platelet count responses, prediction of response, and surgical complications

1 reference

https://api.crossref.org/works/10.1016%2FS0140-6736%2809%2960255-5

7 January 2021

Spleen is a primary site for activation of platelet-reactive T and B cells in patients with immune thrombocytopenic purpura

1 reference

https://api.crossref.org/works/10.1016%2FS0140-6736%2809%2960255-5

7 January 2021

Idiopathic thrombocytopenic purpura: current concepts in pathophysiology and management

1 reference

https://api.crossref.org/works/10.1016%2FS0140-6736%2809%2960255-5

7 January 2021

Multiagent induction and maintenance therapy for patients with refractory immune thrombocytopenic purpura (ITP).

1 reference

https://api.crossref.org/works/10.1016%2FS0140-6736%2809%2960255-5

7 January 2021

Long-term salvage therapy with cyclosporin A in refractory idiopathic thrombocytopenic purpura

1 reference

https://api.crossref.org/works/10.1016%2FS0140-6736%2809%2960255-5

7 January 2021

The efficacy and safety of B-cell depletion with anti-CD20 monoclonal antibody in adults with chronic immune thrombocytopenic purpura

1 reference

https://api.crossref.org/works/10.1016%2FS0140-6736%2809%2960255-5

7 January 2021

One year follow-up of children and adolescents with chronic immune thrombocytopenic purpura (ITP) treated with rituximab

1 reference

https://api.crossref.org/works/10.1016%2FS0140-6736%2809%2960255-5

7 January 2021

Response to B-cell depleting therapy with rituximab reverts the abnormalities of T-cell subsets in patients with idiopathic thrombocytopenic purpura

1 reference

https://api.crossref.org/works/10.1016%2FS0140-6736%2809%2960255-5

7 January 2021

Analysis of regulatory T-cell changes in patients with idiopathic thrombocytopenic purpura receiving B cell-depleting therapy with rituximab

1 reference

https://api.crossref.org/works/10.1016%2FS0140-6736%2809%2960255-5

7 January 2021

Suppression of autoreactive T-cell response to glycoprotein IIb/IIIa by blockade of CD40/CD154 interaction: implications for treatment of immune thrombocytopenic purpura

1 reference

https://api.crossref.org/works/10.1016%2FS0140-6736%2809%2960255-5

7 January 2021

Platelet-associated CD154 in immune thrombocytopenic purpura

1 reference

https://api.crossref.org/works/10.1016%2FS0140-6736%2809%2960255-5

7 January 2021

The effect of anti-CD40 ligand in immune thrombocytopenic purpura

1 reference

https://api.crossref.org/works/10.1016%2FS0140-6736%2809%2960255-5

7 January 2021

New thrombopoietic growth factors

1 reference

https://api.crossref.org/works/10.1016%2FS0140-6736%2809%2960255-5

7 January 2021

Eltrombopag for the treatment of chronic idiopathic thrombocytopenic purpura

1 reference

https://api.crossref.org/works/10.1016%2FS0140-6736%2809%2960255-5

7 January 2021

Efficacy of romiplostim in patients with chronic immune thrombocytopenic purpura: a double-blind randomised controlled trial

1 reference

https://api.crossref.org/works/10.1016%2FS0140-6736%2809%2960255-5

7 January 2021

Safety and efficacy of long-term treatment with romiplostim in thrombocytopenic patients with chronic ITP.

1 reference

https://api.crossref.org/works/10.1016%2FS0140-6736%2809%2960255-5

7 January 2021

Rituximab efficacy and safety in adult splenectomy candidates with chronic immune thrombocytopenic purpura: results of a prospective multicenter phase 2 study

1 reference

https://api.crossref.org/works/10.1016%2FS0140-6736%2809%2960255-5

7 January 2021

Recombinant human thrombopoietin: basic biology and evaluation of clinical studies

1 reference

https://api.crossref.org/works/10.1016%2FS0140-6736%2809%2960255-5

7 January 2021

A unique clonal JAK2 mutation leading to constitutive signalling causes polycythaemia vera

1 reference

https://api.crossref.org/works/10.1016%2FS0140-6736%2809%2960255-5

7 January 2021

Transcriptional regulation of bone marrow thrombopoietin by platelet proteins

1 reference

https://api.crossref.org/works/10.1016%2FS0140-6736%2809%2960255-5

7 January 2021

Peptide agonist of the thrombopoietin receptor as potent as the natural cytokine

1 reference

https://api.crossref.org/works/10.1016%2FS0140-6736%2809%2960255-5

7 January 2021

Recombinant human thrombopoietin attenuates carboplatin-induced severe thrombocytopenia and the need for platelet transfusions in patients with gynecologic cancer.

1 reference

https://api.crossref.org/works/10.1016%2FS0140-6736%2809%2960255-5

7 January 2021

Thrombocytopenia caused by the development of antibodies to thrombopoietin

1 reference

https://api.crossref.org/works/10.1016%2FS0140-6736%2809%2960255-5

7 January 2021

A non-peptide compound which can mimic the effect of thrombopoietin via c-Mpl

1 reference

https://api.crossref.org/works/10.1016%2FS0140-6736%2809%2960255-5

7 January 2021

AMG531 stimulates megakaryopoiesis in vitro by binding to Mpl.

1 reference

https://api.crossref.org/works/10.1016%2FS0140-6736%2809%2960255-5

7 January 2021

Pharmacodynamics and pharmacokinetics of AMG 531, a novel thrombopoietin receptor ligand

1 reference

https://api.crossref.org/works/10.1016%2FS0140-6736%2809%2960255-5

7 January 2021

Discovery and characterization of a selective, nonpeptidyl thrombopoietin receptor agonist.

1 reference

https://api.crossref.org/works/10.1016%2FS0140-6736%2809%2960255-5

7 January 2021

Induction of megakaryocytopoiesis and thrombocytopoiesis by JTZ-132, a novel small molecule with thrombopoietin mimetic activities

1 reference

https://api.crossref.org/works/10.1016%2FS0140-6736%2809%2960255-5

7 January 2021

A novel therapeutic approach for thrombocytopenia by minibody agonist of the thrombopoietin receptor

1 reference

https://api.crossref.org/works/10.1016%2FS0140-6736%2809%2960255-5

7 January 2021

A rationally designed agonist antibody fragment that functionally mimics thrombopoietin

1 reference

https://api.crossref.org/works/10.1016%2FS0140-6736%2809%2960255-5

7 January 2021

Phase 1 clinical study of eltrombopag, an oral, nonpeptide thrombopoietin receptor agonist

1 reference

https://api.crossref.org/works/10.1016%2FS0140-6736%2809%2960255-5

7 January 2021

Pharmacodynamics and pharmacokinetics of AMG 531, a thrombopoiesis-stimulating peptibody, in healthy Japanese subjects: a randomized, placebo-controlled study.

1 reference

https://api.crossref.org/works/10.1016%2FS0140-6736%2809%2960255-5

7 January 2021

An open-label, unit dose-finding study of AMG 531, a novel thrombopoiesis-stimulating peptibody, in patients with immune thrombocytopenic purpura

1 reference

https://api.crossref.org/works/10.1016%2FS0140-6736%2809%2960255-5

7 January 2021

AMG 531, a thrombopoiesis-stimulating protein, for chronic ITP.

1 reference

https://api.crossref.org/works/10.1016%2FS0140-6736%2809%2960255-5

7 January 2021

Antiphospholipid antibodies in adults with immune thrombocytopenic purpura

1 reference

https://api.crossref.org/works/10.1016%2FS0140-6736%2809%2960255-5

7 January 2021

A novel nonpeptidyl human c-Mpl activator stimulates human megakaryopoiesis and thrombopoiesis

1 reference

https://api.crossref.org/works/10.1016%2FS0140-6736%2809%2960255-5

7 January 2021

Interferon-alpha 2b-induced thrombocytopenia is caused by inhibition of platelet production but not proliferation and endomitosis in human megakaryocytes

1 reference

https://api.crossref.org/works/10.1016%2FS0140-6736%2809%2960255-5

7 January 2021

AKR-501 (YM477) in combination with thrombopoietin enhances human megakaryocytopoiesis

1 reference

https://api.crossref.org/works/10.1016%2FS0140-6736%2809%2960255-5

7 January 2021

The effect of a novel, small non-peptidyl molecule butyzamide on human thrombopoietin receptor and megakaryopoiesis

1 reference

https://api.crossref.org/works/10.1016%2FS0140-6736%2809%2960255-5

7 January 2021

R406, an orally available spleen tyrosine kinase inhibitor blocks fc receptor signaling and reduces immune complex-mediated inflammation

1 reference

https://api.crossref.org/works/10.1016%2FS0140-6736%2809%2960255-5

7 January 2021

An orally bioavailable spleen tyrosine kinase inhibitor delays disease progression and prolongs survival in murine lupus

1 reference

https://api.crossref.org/works/10.1016%2FS0140-6736%2809%2960255-5

7 January 2021

Eltrombopag for thrombocytopenia in patients with cirrhosis associated with hepatitis C.

1 reference

https://api.crossref.org/works/10.1016%2FS0140-6736%2809%2960255-5

7 January 2021

The role of AMG-531 in the treatment of thrombocytopenia in idiopathic thrombocytopenic purpura and myelodysplastic syndromes

1 reference

https://api.crossref.org/works/10.1016%2FS0140-6736%2809%2960255-5

7 January 2021

Overview of thrombopoietic agents in the treatment of thrombocytopenia

1 reference

https://api.crossref.org/works/10.1016%2FS0140-6736%2809%2960255-5

7 January 2021

Thrombopoietin inhibits nerve growth factor-induced neuronal differentiation and ERK signalling

1 reference

https://api.crossref.org/works/10.1016%2FS0140-6736%2809%2960255-5

7 January 2021

Human thrombopoietin reduces myocardial infarct size, apoptosis, and stunning following ischaemia/reperfusion in rats

1 reference

https://api.crossref.org/works/10.1016%2FS0140-6736%2809%2960255-5

7 January 2021

Management of patients with refractory immune thrombocytopenic purpura

1 reference

https://api.crossref.org/works/10.1016%2FS0140-6736%2809%2960255-5

7 January 2021

Improved quality of life for romiplostim-treated patients with chronic immune thrombocytopenic purpura: results from two randomized, placebo-controlled trials

1 reference

https://api.crossref.org/works/10.1016%2FS0140-6736%2809%2960255-5

7 January 2021

Effects of eradication of Helicobacter pylori infection in patients with immune thrombocytopenic purpura: a systematic review

1 reference

https://api.crossref.org/works/10.1016%2FS0140-6736%2809%2960255-5

7 January 2021

Paths to understanding the genetic basis of autoimmune disease

1 reference

https://api.crossref.org/works/10.1016%2FS0140-6736%2809%2960255-5

7 January 2021

10.1016/S0140-6736(09)60255-5

Identifiers

DOI

1 reference

26 July 2017

1 reference